Distribution of the High-Affinity Binding Site and Intracellular Target of Botulinum Toxin Type A in the Human Bladder

European Urology

Volumn 57, Issue 5, 2010, Pages 884-890

  Coelho, Ana ^a,b   Dinis, Paolo ^b,c   Pinto, Rui ^c   Gorgal, Tiago ^c   Silva, Carlos ^c   Silva, André ^c   Silva, João ^c   Cruz, Célia D ^a,b   Cruz, Francisco ^b,c   Avelino, António ^a,b  

^a Institute of Pharmacology and Therapeutics   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Bladder; Botulinum toxin; Detrusor; Innervation; SNAP 25; SV2; Urothelium

Indexed keywords

BOTULINUM TOXIN A; MEMBRANE PROTEIN; SYNAPTIC VESICLE PROTEIN 2; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BLADDER; BLADDER MUSCLE; CADAVER; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; IMMUNOFLUORESCENCE; PARASYMPATHETIC NERVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SENSORY NERVE; SYMPATHETIC NERVE; UROTHELIUM;

ADULT; AGED; BINDING SITES; BOTULINUM TOXINS, TYPE A; CADAVER; HUMANS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; NEUROTOXINS; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; URINARY BLADDER; YOUNG ADULT;

EID: 77949654631     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.12.022     Document Type: Article

References (30)

1. Apostolidis A., Dasgupta P., Denys P., et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 55 (2009) 100-120
2. ®) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 53 (2008) 275-287
3. Silva C.M., and Cruz F. Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?. Curr Opin Urol 19 (2009) 347-352
4. Gamé X., Mouracade P., Chartier-Kastler E., et al. Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. J Pediatr Urol 5 (2009) 156-164
5. Giannantoni A., Mearini E., Del Zingaro M., and Porena M. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results. Eur Urol 55 (2009) 705-712
6. Simpson L.L. The action of botulinal toxin. Rev Infect Dis 1 (1979) 656-662
7. Chancellor M.B., Fowler C.J., Apostolidis A., et al. Drug insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol 5 (2008) 319-328
8. Dong M., Yeh F., Tepp W.H., et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 312 (2006) 592-596
9. Shen J., Ma J., Lee C., Smith T.L., Tan K.H., and Koman L.A. How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: study in juvenile rats. J Orthop Res 24 (2006) 1128-1135
10. Jurasinski C.V., Lieth E., Dang Do A.N., and Schengrund C.L. Correlation of cleavage of SNAP-25 with muscle function in a rat model of botulinum neurotoxin type A induced paralysis. Toxicon 39 (2001) 1309-1315
11. Bucley K., and Kelly R.B. Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J Cell Biol 100 (1985) 1284-1294
12. Avelino A., Cruz C., Nagy I., and Cruz F. Vanilloid receptor 1 expression in the rat urinary tract. Neuroscience 109 (2002) 787-798
13. Dixon J.S., Jen P.Y., and Gosling J.A. The distribution of vesicular acetylcholine transporter in the human male genitourinary organs and its co-localization with neuropeptide Y and nitric oxide synthase. Neurourol Urodyn 19 (2000) 185-194
14. Gosling J.A., Dixon J.S., and Jen P.Y.P. The distribution of noradrenergic nerves in the human lower urinary tract. A review. Eur Urol 36 Suppl 1 (1999) 23-30
15. Holzer P. Role of visceral afferent neurons in mucosal inflammation and defense. Curr Opin Pharmacol 7 (2007) 563-569
16. Wiseman O.J., Fowler C.J., and Landon D.N. The role of the human bladder lamina propria myofibroblast. BJU Int 91 (2003) 89-93
17. Roosen A., Datta S.N., Chowdhury R.A., et al. Suburothelial myofibroblasts in the human overactive bladder and the effect of botulinum neurotoxin type A treatment. Eur Urol 55 (2009) 1440-1449
18. Smet P.J., Moore K.H., and Jonavicius J. Distribution and co-localization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder. Lab Invest 77 (1997) 37-49
19. Hughes B., and Whaler B.C. Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by Cl. botulinum type A toxin. J Physiol 160 (1962) 221-233
20. Eleopra R., Tugnoli V., and De Grandis D. The variability in the clinical effect induced by botulinum toxin type A: the role of muscle activity in humans. Mov Disord 12 (1997) 89-94
21. Rummel A., Mahrold S., Bigalke H., and Binz T. The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol 51 (2004) 631-643
22. Apostolidis A., Dasgupta P., and Fowler C.J. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49 (2006) 644-650
23. Reitz A., Stöhrer M., Kramer G., et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45 (2004) 510-515
24. Vlaskovska M., Kasakov L., Rong W., et al. P2X3 knock-out mice reveal a major sensory role for urothelially released ATP. J Neurosci 21 (2001) 5670-5677
25. Vemulakonda V.M., Somogyi G.T., Kiss S., Salas N.A., Boone T.B., and Smith C.P. Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation. J Urol 173 (2005) 621-624
26. Rapp D.E., Turk K.W., Bales G.T., and Cook S.P. Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 175 (2006) 1138-1142
27. Morenilla-Palao C., Planells-Cases R., García-Sanz N., and Ferrer-Montiel A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 279 (2004) 25665-25672
28. Gosling J.A. Modification of bladder structure in response to outflow obstruction and ageing. Eur Urol 32 Suppl 1 (1997) 9-14
29. Brady C.M., Apostolidis A.N., Harper M., et al. Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 93 (2004) 770-776
30. Smith C.P., Franks M.E., McNeil B.K., et al. Effect of botulinum toxin type A on the autonomic nervous system of the rat lower urinary tract. J Urol 169 (2003) 1896-1900